SMMT
Summit Therapeutics Inc.
Nasdaq: SMMT · Miami, FL · Healthcare
$15.47-0.08 (-0.51%)Closed
Market Cap$12.27B
Cash$419.4Mmost recent
Runway10 mo$122.3M Q burn
P/E (TTM)—EPS $-1.44
52-Wk Range$12.43 – $26.38
Avg Volume4.2M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$15.47-20.5%
Pipeline
Drug candidates sponsored by Summit Therapeutics · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 3 | Ridinilazole | Clostridioides Difficile Infection+1 more | Completed | 2021-11-17past | 3 | |
| Phase 3 | AK112 Injection | Non-Squamous Non-small Cell Lung Cancer | Active, not recruiting | 2025-04-12past | 1 | |
| Phase 3 | Ivonescimab Injection | Non-Small Cell Lung Cancer | Recruiting | 2028-04 | 2 | |
| Phase 3 | Drug: Ivonescimab Injection | Metastatic Colorectal Cancer (CRC) | Recruiting | 2028-05-31 | 1 | |
| Phase 2 | Ivonescimab Dose 1 | Metastatic Urothelial Carcinoma+1 more | Recruiting | 2030-10-31 | 1 | |
| Phase 2 | SMT19969 | Clostridium Difficile Infection | Completed | 2015-10past | 1 | |
| Phase 2 | Ezutromid | Duchenne Muscular Dystrophy | Terminated | 2018-04-11past | 1 | |
| Phase 2 | Ivonescimab (dose level 1) combined with Cadonilimab | Renal Cell Carcinoma, Clear Cell | Not yet recruiting | 2029-04-12 | 1 | |
| Phase 1 | SMT C1100 | Duchenne Muscular Dystrophy+1 more | Completed | 2015-08past | 2 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for SMMT. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.